Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Head_&_Shoulders,_Inc.
gptkb:Ranitidine |
| gptkbp:activities |
inhibits ergosterol synthesis
|
| gptkbp:approves |
gptkb:FDA
gptkb:EMA |
| gptkbp:brand |
gptkb:Nizoral
|
| gptkbp:can_be_used_with |
gptkb:beer
|
| gptkbp:contraindication |
liver disease
pregnancy breastfeeding |
| gptkbp:developed_by |
gptkb:Janssen_Pharmaceutica
|
| gptkbp:discovered_by |
1970s
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
Ketoconazole
|
| gptkbp:ingredients |
C26 H28 Cl2 N4 O4 S
|
| gptkbp:interacts_with |
gptkb:cyclosporine
gptkb:warfarin benzodiazepines |
| gptkbp:is_analyzed_in |
hormonal therapies
antifungal resistance |
| gptkbp:is_associated_with |
drug interactions
QT prolongation |
| gptkbp:is_atype_of |
J02 A C01
|
| gptkbp:is_available_in |
gptkb:various_countries
|
| gptkbp:is_available_on |
gptkb:tablet
gptkb:skincare_product |
| gptkbp:is_considered |
first-line treatment for certain fungal infections
second-line treatment for others |
| gptkbp:is_part_of |
combination therapy
treatment protocols antifungal therapy clinical guidelines for antifungal treatment |
| gptkbp:is_studied_in |
new formulations
alternative delivery methods |
| gptkbp:is_subject_to |
prescription regulations
|
| gptkbp:is_used_for |
fungal infections
seborrheic dermatitis candidiasis tinea infections |
| gptkbp:is_used_in |
treatment of prostate cancer
treatment of Cushing's syndrome |
| gptkbp:manager |
oral
topical |
| gptkbp:metabolism |
liver enzymes
|
| gptkbp:side_effect |
dizziness
headache nausea liver toxicity |
| gptkbp:suitable_for |
gptkb:Person
elderly patients patients with adrenal insufficiency |
| gptkbp:type_of |
65277-42-1
|